The global rheumatoid arthritis drugs market will reach $47bn in 2024

Thursday, February 7, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Biologics, Non-Biologics, NSAIDs, sDMARDs and OthersThe global rheumatoid arthritis

drugs market will reach $47bn in 2024. In 2018, the Biologics submarket held 87% of the Global Rheumatoid Arthritis drugs market.Read the full report: https://www.reportlinker.com/p05731223 How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.In this brand new 232-page report you will receive 234 charts– all unavailable elsewhere.The 232-page report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.By ordering and reading our brand-new report today you stay better informed and ready to act.Report Scope• Global Rheumatoid Arthritis Market from 2019-2029Forecast of the Global Rheumatoid Arthritis market by Submarket:• Biologics• Non-Biologics: NSAIDs, sDMARDs and OthersForecast of the leading drugs in the Global Rheumatoid Arthritis market:• Humira• Enbrel• Remicade• Rituxan/MabThera• Simponi/Simponi Aria• Orencia• Actemra/Roactemra• Cimzia• Celebrex• Xeljanz• Arcoxia• OthersThis report provides individual revenue forecasts to 2029 for these regional and national markets:North America: US, CanadaEurope: Germany, France, United Kingdom, Italy, Spain, Russia and rest of EuropeAsia-Pacific: Japan, China, India and rest of Asia-PacificLatin America: Brazil, Mexico, Rest of Latin AmericaMiddle East & Africa: Saudi Arabia, South Africa, Rest of MEAEach regional market is further segmented into Biologics, Non-Biologics, NSAIDs, sDMARDs and OthersOur study discusses the selected leading companies that are the major players in the rheumatoid arthritis market:• AbbVie• Amgen• AstraZeneca• BMS• Eli Lilly• Johnson & Johnson• Merck & Co• Novartis• Pfizer• Roche• Sanofi• UCB• Our study discusses selected compounds under development for rheumatoid arthritis.This study provides a SWOT and STEP analysis of the rheumatoid arthritis drugs market.Visiongain's study is intended for anyone requiring commercial analyses for the rheumatoid arthritis market. You find data, trends and predictions.Read the full report: https://www.reportlinker.com/p05731223 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-global-rheumatoid-arthritis-drugs-market-will-reach-47bn-in-2024-300790834.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store